translation agency

NLM AIDSLINE
Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS [see comments]
Jacobson MA; Wilson S; Stanley H; Holtzer C; Cherrington J; Safrin S;
August 30, 1999
Clin Infect Dis. 1999 Mar;28(3):528-33. Unique Identifier : AIDSLINE

Ganciclovir and cidofovir, two antiviral agents used in the treatment of cytomegalovirus (CMV) retinitis, have a synergistic effect inhibiting CMV replication in vitro. In a phase I study, seven patients with AIDS-related CMV retinitis were treated with cidofovir (5 mg/kg intravenously every 2 weeks) combined with ganciclovir (1 g orally three times a day). During a median of 5.5 months (range, 1-12 months) of combined therapy, only one patient had retinitis progression, and only two of 28 blood cultures (specimens of which were obtained on a monthly basis) yielded CMV. Dose-limiting adverse ocular effects (anterior uveitis [two patients] and hypotony [two patients]) occurred in three of seven patients. The results suggest that combination therapy with intravenous cidofovir and oral ganciclovir (a regimen that does not require indwelling central venous catheter access) might enhance clinical efficacy. Less frequent administration of cidofovir in combination with oral ganciclovir should be prospectively studied to determine if the incidence of treatment-associated toxicity might be reduced.

CLINICAL TRIAL CLINICAL TRIAL, PHASE I JOURNAL ARTICLE Adult Antiviral Agents/ADVERSE EFFECTS/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/*DRUG THERAPY Cytomegalovirus Retinitis/*DRUG THERAPY Cytosine/*ANALOGS & DERIVATIVES/ADVERSE EFFECTS/THERAPEUTIC USE Drug Therapy, Combination Female Ganciclovir/ADVERSE EFFECTS/*THERAPEUTIC USE Human Male Middle Age Organophosphorus Compounds/ADVERSE EFFECTS/*THERAPEUTIC USE Treatment Outcome

www.aegis.org